The University of Michigan School of Public Health is among 13 institutions that will receive funding from the Centers for Disease Control and Prevention as part of a network of centers focused on predicting and preparing for future disease outbreaks.
According to a new study published in the journal Clinical Infectious Diseases, while there have been major advances over the last decade in an effort to improve the effectiveness of seasonal influenza vaccine, innovative approaches are needed to significantly improve vaccine effectiveness. Study author Arnold Monto, professor of Epidemiology at the University of Michigan School of Public Health, discusses the findings.
For outstanding contributions to respiratory virus disease research over the course of his career, Dr. Arnold Monto, the Thomas Francis, Jr. Collegiate Professor of Public Health, has received the Lifetime Achievement Award from the International Society for Influenza and other Respiratory Virus Diseases (ISIRV).
A recurring sentiment among some in the vaccine-hesitant community is a desire to wait to receive any of the three available COVID-19 vaccines until they have been officially approved by the Food and Drug Administration. And while the FDA has authorized the Pfizer, Moderna and Johnson & Johnson vaccines―and is expected to also approve each one in turn―for many people, the difference between “authorized” and “approved” has been confusing.
Reinfections of seasonal coronaviruses are frequent, according to new research that suggests that the coronavirus behind the current pandemic could also produce reinfections.
Several states are loosening their coronavirus restrictions on restaurants and other businesses because of improved infection and hospitalization numbers but are moving cautiously, in part because of the more contagious variant taking hold.